Unknown

Dataset Information

0

Crystallization and preliminary X-ray diffraction analysis of kanamycin-binding ?-lactamase in complex with its ligand.


ABSTRACT: TEM-1 ?-lactamase is a highly efficient enzyme that is involved in bacterial resistance against ?-lactam antibiotics such as penicillin. It is also a robust scaffold protein which can be engineered by molecular-evolution techniques to bind a variety of targets. One such ?-lactamase variant (BlaKr) has been constructed to bind kanamycin (kan) and other aminoglycoside antibiotics, which are neither substrates nor ligands of native ?-lactamases. In addition to recognizing kan, BlaKr activity is up-regulated by its binding via an activation mechanism which is not yet understood at the molecular level. In order to fill this gap, determination of the structure of the BlaKr-kan complex was embarked upon. A crystallization condition for BlaKr-kan was identified using high-throughput screening, and crystal growth was further optimized using streak-seeding and hanging-drop methods. The crystals belonged to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a = 47.01, b = 72.33, c = 74.62?Å, and diffracted to 1.67?Å resolution using synchrotron radiation. The X-ray structure of BlaKr with its ligand kanamycin should provide the molecular-level details necessary for understanding the activation mechanism of the engineered enzyme.

SUBMITTER: Van de Water K 

PROVIDER: S-EPMC3107148 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Crystallization and preliminary X-ray diffraction analysis of kanamycin-binding β-lactamase in complex with its ligand.

Van de Water Karen K   Soror Sameh H SH   Wohlkonig Alexandre A   van Nuland Nico A J NA   Volkov Alexander N AN  

Acta crystallographica. Section F, Structural biology and crystallization communications 20110526 Pt 6


TEM-1 β-lactamase is a highly efficient enzyme that is involved in bacterial resistance against β-lactam antibiotics such as penicillin. It is also a robust scaffold protein which can be engineered by molecular-evolution techniques to bind a variety of targets. One such β-lactamase variant (BlaKr) has been constructed to bind kanamycin (kan) and other aminoglycoside antibiotics, which are neither substrates nor ligands of native β-lactamases. In addition to recognizing kan, BlaKr activity is up-  ...[more]

Similar Datasets

| S-EPMC3212460 | biostudies-literature
| S-EPMC2935245 | biostudies-literature
| S-EPMC3758161 | biostudies-literature
| S-EPMC2339750 | biostudies-literature
| S-EPMC2496858 | biostudies-literature
| S-EPMC4259221 | biostudies-literature
| S-EPMC1952356 | biostudies-literature
| S-EPMC4051543 | biostudies-literature
| S-EPMC3253844 | biostudies-literature
| S-EPMC3253832 | biostudies-literature